In a recent GMP Review article (Vol 13, No. 2 July 2014), The maturing world of ATMP manufacture, by Drew Hope, HypoThermosol® FRS was cited as a promising short-term, cryopreservation-free, cold-chain supply solution. HypoThermosol’s high osmotic concentrations and free-radical scavenging properties provide cold stability (2-8° C) for several days, and is currently being used in over 130 customer clinical trials.
Under terms of a three-year agreement with Somahlution LLC, a Jupiter, Florida-based biotechnology company, BioLife will manufacture DuraGraft, a tissue preservation solution for storage of harvested veins used in coronary artery bypass graft (CABG) and other vascular access surgeries. Unlike existing potentially cytocidal and clinically-unproven solutions, DuraGraft is the first Endothelial Damage Inhibitor (EDI) that uniquely protects vascular endothelium and its associated architecture.
|BioLife Solutions announced on June 11th, 2014, that it received Frost & Sullivan’s 2014 North American Biopreservation Media Technology Innovation Leadership Award.
The award is given to a Biotech company that has demonstrated a commitment to innovation, commercialization success, application diversity, and fulfillment of unmet needs in the company’s strategic markets. Please see entire press release.
BioLife Solutions’ clinical grade biopreservation media continues to gain adoption over traditional “home-brew” reagent cocktails, according to a recent article in BioPharma-Reporter.com. Please see Cell-based drugs drive cryo-freeze tech over ‘home-brewed cocktails’.
In related news released last week, BioLife Solutions announced that Natick, Massachusetts-based Parcell Laboratories has adopted BioLife’s CryoStor clinical grade cell and tissue freeze media for use in future clinical trials of Early Lineage Adult (ELA) stem cell-potential therapies, for which Parcell holds an exclusive worldwide license. Please see BioLife Solutions CryoStor® Freeze Media Adopted by Parcell Laboratories for Stem Cells to be Studied in Clinical Trials.
BioLife Solutions is pleased to announce a new “link” in our biopreservation chain of quality products.
Our Precision Thermal Shippers, manufactured by SAVSU Technologies, utilize nano-porous, amorphous silica technology to produce shipping containers that are durable, reusable, and offer advanced temperature stability during transit.
The CryoQ™ Shipper is designed for small volumes of bio-material that need to be shipped with dry ice at extremely stable deep frozen temperatures; -80 to -60°C.
The PhD™ unit is for materials which must be maintained at 2-8° C. Phase change material keeps payload from warming or freezing out of target cold temperature range of 2-8° C.
Each unit is made to order, customizing payload boxes to suit vial, syringe and other bio-container sizes.
BioLife Solutions is proud to have been named to the prestigious Deloitte Technology Fast 500TM 2013 list. Winners were announced in a Deloitte press release on November 13th. Mike Rice, BioLife’s CEO, accepted the award at Deloitte’s Washington State Awards Celebration/Powerful Connections, November 14th in Seattle.
The Deloitte Technology Fast 500TM is the pre-eminent technology awards program in United States and Canada with 2013 being its Nineteenth anniversary. Combining technological innovation, entrepreneurship and rapid growth, Fast 500 companies – large, small, public and private – span a variety of industry sectors, and are leaders in hardware, software, telecom, semiconductors, life sciences and emerging areas, such as clean technology.In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues.
Mike Rice, BioLife Solutions CEO, remarked, “Being recognized on the Deloitte Fast Technology 500TM is a great accomplishment for our entire team.” Earlier this year, BioLife was named as one of Washington’s 100 Best Companies to Work For, and also received regional recognition as one of the Largest Biotechnology Companies by Puget Sound Business Journal.
Donald Hudspeth, Chief Operating Officer of Lifeforce Cryobanks cord blood bank, presented Improving the Protection and Recovery of CB Stem Cells at the Terrapinn World Cord Blood Congress held in Cambridge, MA on Sept 30th-Oct 1st. Hudspeth highlighted their Best Practices-inspired PremierMaxCBSM cord blood stem cell processing method, which utilizes PrepaCyte® CB for red blood cell depletion and CryoStor® for cryopreservation of the cord blood stem cell product. The presentation shared data demonstrating improved cell recovery, viability, and functionality compared to their previous historical home-brew methods. This presentation represents the second time in the last four months that Lifeforce Cryobanks’ PremierMaxCB has been highlighted at a leading cord blood conference, following the presentation of their poster Reduced Engraftment Times using the PremierMaxCBSM Processing Methodology at the 2013 International Cord Blood Symposium. The presentation is available for viewing here. The International Cord Blood symposium poster is also available for viewing here.
In news released yesterday, BioLife Solutions announced an expansion of its relationship with Vancouver, BC-based STEMCELL Technologies Inc. Since August 2009, STEMCELL Technologies has distributed BioLife’s best in class biopreservation media products to the worldwide research and clinical biobanking communities.
In an expansion of the relationship, STEMCELL Technologies recently selected BioLife’s CryoStor cGMP freeze media for use in the launch of over 50 new primary cell products (from bone marrow, peripheral blood, umbilical cord blood, and umbilical cord tissue), to be marketed to the research community.
Mike Rice, BioLife Solutions President and CEO, commented on STEMCELL’s product launch by stating, “We are quite pleased that STEMCELL Technologies has incorporated CryoStor into this new cell product portfolio. This is further validation of the superior preservation efficacy and overall value proposition of pre-formulated CryoStor when used with blood-derived cell types. We look to future growth in our business with STEMCELL Technologies and are glad to see our intellectual property enabling a revenue source for this strategic distributor.”
A February 2013 report by visiongain predicts that the world market for cell-based assays will reach $4.7 billion in 2016.
David Llewellyn, Ph.D., MBA, Senior Director, Business Operations of STEMCELL Technologies commented on the expansion of the relationship with BioLife; “We have been very pleased with the performance of BioLife’s products and the company’s overall support. BioLife has become an increasingly strategic supplier of our research products. Our customers value the quality and performance of BioLife’s biopreservation media products. Along with our own internal research, customer feedback gives us confidence to incorporate CryoStor into our new primary cell product portfolio.”